Kataoka Masaharu, Satoh Toru, Manabe Tomohiro, Anzai Toshihisa, Yoshikawa Tsutomu, Mitamura Hideo, Ogawa Satoshi
Cardiopulmonary Division, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582.
Intern Med. 2004 Oct;43(10):945-50. doi: 10.2169/internalmedicine.43.945.
We report a 48-year-old woman with right heart failure due to primary pulmonary hypertension. Continuous infusion of epoprostenol (prostaglandin I2) for 1.5 years failed to control her condition, but she was later successfully treated with additional sildenafil for a few months. Her mean pulmonary artery pressure was originally 57 mmHg, increased to 62 mmHg with epoprostenol, and decreased to 45 mmHg with sildenafil. Additional sildenafil may be an effective and life-saving agent in patients with primary pulmonary hypertension who show a poor response to epoprostenol, which is considered to be very powerful medical treatment for the disease.
我们报告了一名48岁因原发性肺动脉高压导致右心衰竭的女性患者。持续输注依前列醇(前列腺素I2)1.5年未能控制其病情,但她后来加用西地那非治疗数月后获得成功。她的平均肺动脉压最初为57 mmHg,使用依前列醇后升至62 mmHg,而使用西地那非后降至45 mmHg。对于对依前列醇反应不佳的原发性肺动脉高压患者,加用西地那非可能是一种有效且挽救生命的药物,依前列醇被认为是针对该疾病非常强效的药物治疗。